Consensus ORIC Pharmaceuticals, Inc. Börse Stuttgart

Stocks

4TZ

US68622P1093

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 14:04:17 2026-07-07 EDT			5-day change	1st Jan Change
9.512 ^EUR	-0.21%		+8.52%	+38.14%

06-09	ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08:00 AM
05-04	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

618dc9bc9a4eba87d0d1cf3b7.2Izmu5cGukyAkPHB5l6J9S2RqIOqy0RQbSvcw5d_g1c.gduE09Jljy_F-qOFgT_Hh3zn5rXivRNiPmifoK9G-h2x_ZfU9HD4L_jhgg~603bf97f7f44956de09de9ba910a25d8

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

04-01	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
01-07	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
11-14	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
25-05-06	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
24-10-31	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
24-10-31	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
24-09-06	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
24-08-13	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
24-03-27	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
24-03-21	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
24-03-12	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
24-03-01	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
24-02-26	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
23-12-13	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
23-12-12	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
23-10-26	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
23-10-24	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
23-10-23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
23-09-22	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
23-08-16	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
23-08-15	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
23-05-10	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT
23-04-05	Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	MT
23-03-23	HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16	MT
23-03-21	Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARGENX SE					+8.88%
	WUXI APPTEC CO., LTD.					+19.1%
	BIONTECH SE					+30.09%
	INSMED INCORPORATED					+76.66%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.66%
	GENMAB A/S					+26.94%
	PHARMAESSENTIA CORPORATION					-21.65%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+4.61%
	EXELIXIS, INC.					-9.85%
	Average					+17.60%
	Weighted average by Cap.					+19.00%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.91USD

Average target price

20.29USD

Spread / Average Target

+85.94%

High Price Target

25.00USD

Spread / Highest target

+129.15%

Low Price Target

14.00USD

Spread / Lowest Target

+28.32%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
Piper Sandler
Oppenheimer
Wells Fargo Securities
JonesTrading Institutional Services
JPMorgan Chase
HC Wainwright
Baird
Cantor Fitzgerald
Citigroup
Guggenheim